Recent，The second quarterly report of each pharmaceutical company is released，Firstword website, the value added of sales compared to the first half of last year by comparing various drugs，List 18 drugs with the largest increase in sales in the first half of this year。

 

 

  BMS two major drugs before

 

  PD-1 inhibitors of Bristol-Myers Squibb (Bristol-Myers Squibb) Opdivo led far ahead with an increase of 1.382 billion US dollars，The top of the largest sales increase in the first half of this year's sales of the largest drug T0 18，The sales revenue of the drug in the first half of this year was $ 1.544 billion，and only Stake Sports Betting$ 162 million in the same period last year。

 

  OPDIVO is expected to be approved to treat a series of tumors，Among them, second -line therapy for second -line therapy for non -small cell lung cancer (NSCLC) is most worth looking forward to。Originally OPDIVO's sales growth in the next 6 to 12 months will attract more attention，But it has not been able to show birth and benefit in NSCLC's first -line treatment recently，Now KEYTRUDA, a competitor Merck, will be expected to win this competition first。

 

  but，From the recent movement，Investors' attention to Beltay Schimbao has been divergent from OPDIVO，The manifestation of new anticoagulant drug Eliquis shifted to the company's diversification from the field of tumor immunotherapy in the tumor immunotherapy in the dominant position。Although the drug has a lower speed of the medicine than expected，But at present, its incremental increase exceeds the Bayer and Johnson & Johnson) The cooperation with Xarelto。

 

  The outstanding performance of the two drugs shows the industry the momentum of continuous high -speed growth of new anticoagulant drugs，This is mainly due to the transition from Huafrin to the new anticoagulant drug。Where，Ai Ley has increased its sales in the first half of the year with sales of $ 719 million。Bayero's sales increased by $ 573 million，Leading 7，Among them, Bayer contributed 325 million US dollars，Johnson & Johnson contributed $ 248 million。

 

  After OPDIVO，ABBVIE's inflammatory therapy drug Humira successfully seized stake online sports bettingthe second largest position in the first half of the year's sales increase。Current，This medicine is the world's largest best -selling medicine，But the sales revenue in the first half of 2016 increased by only 1.078 billion US dollars compared with the same period in 2015。The important strategy of Albervi is how to re -invest in repairing Merlot's profits，So as the challenge of biological drugs is coming，Can maintain stable sales growth through new products。

 

  Pfizer's latest launch of breast cancer treatment drugs IBRANCE picking up the third place in the first half of the year's largest drug T0P 18 list，Its sales increased by $ 764 million。The strong performance of the medicine also means that Eli Lilly and Novartis will only be able to compete for the second position in this type of drug with academic ability。

 

  GSK Anti -HIV drugs focus

 

  Regeneron and Bayer's elderly macular transgender therapy drugs Eylea continue to show strong growth，Although the medicine is facing the LUCENTIS，and the challenge of Avastin's Avastin。Abercip's sales revenue in the first half of the year increased by $ 682 million，Leading 5，Among them, the renewable yuan contributed 416 million US dollars，Bayer contributed $ 266 million。

 

  Andrew Witty, CEO of Glaxosmithkline, will make a stick in March next year，Its successor will face the challenge of the treatment of the treatment of respiratory diseases，Although the company is the ruler of this field，But the situation is deteriorating sharply。

 

  Glaxo Sonsk will also stake online sports bettingmake every effort to carry out the sales of AIDS therapy drug Triumeq，This medicine is from dolutegravir、Sanlian Compound Pharmaceuticals composed of Abba Camvavir and Ramov Ding，His good performance in the field of AIDS therapy。In addition，In this field, there is also the newly listed by Gilead Sciences of Gilead Science、Enquatabin、COBICISTAT and tidelofovirirahophenophenophelamine pomosic acid Genvoya。Where，Triumeq became the 6th largest drug in the first half of the year with its sales growth with a sales growth of $ 659 million。and Genvoya's sales growth is only 460 million US dollars，9th in the list。

 

  Current，The industry unanimously predicts Triumeq is expected to reach an annual sales of $ 6 billion in 2020，and Genvoya's initial performance is largely ignored。Foreign attention from Geely is mainly focused on the decline in the sales revenue of hepatitis C drugs，and the mergers and acquisitions that are mainly based on the R & D line to be carried out。

 

  For the new foundation medicine (Celgene)，Revlimid (Revlimid) of blood system tumor therapy has successfully ranked among the best -selling anti -tumor drugs in the world，Its sales growth in the first half of the year was 487 million US dollars，8th in the list。This drug has recently encountered frustration in clinical trials of large B -cell lymphoma.。In addition，Psoriasis arthritis therapy for psoriasis in Xinji Pharmaceuticals continues to perform well。The medicine was successfully stake betting appon the list with a sales growth of US $ 288 million，rank 15th in position。

 

  Cosentyx, the most successful new drug on the market by Novartis，With a sales growth of $ 384 million, it ranks 12th in the list。